MCID: ADN089
MIFTS: 48

Adenosquamous Lung Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Adenosquamous Lung Carcinoma

MalaCards integrated aliases for Adenosquamous Lung Carcinoma:

Name: Adenosquamous Lung Carcinoma 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:4829
NCIt 50 C9133
UMLS 73 C0279557

Summaries for Adenosquamous Lung Carcinoma

Disease Ontology : 12 An adenosquamous carcinoma located in lung that derives from lung tissue composed of at least 10% by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells.

MalaCards based summary : Adenosquamous Lung Carcinoma is related to malignant peritoneal mesothelioma and rare adenocarcinoma of the breast. An important gene associated with Adenosquamous Lung Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Gefitinib and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, lung and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Adenosquamous lung carcinoma (AdSqLC) is a biphasic malignant tumor arising from lung tissue that is... more...

Related Diseases for Adenosquamous Lung Carcinoma

Diseases related to Adenosquamous Lung Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 10.3 BIRC5 EGFR
2 rare adenocarcinoma of the breast 10.3 KRAS PIK3CA
3 sigmoid neoplasm 10.2 HRAS KRAS
4 prostate adenoid cystic carcinoma 10.2 HRAS PIK3CA
5 periampullary adenoma 10.2 HRAS KRAS
6 dermatosis papulosa nigra 10.2 FGFR3 PIK3CA
7 adenosquamous carcinoma 10.2 EGFR KRAS PIK3CA
8 schimmelpenning-feuerstein-mims syndrome 10.2 HRAS KRAS
9 ethmoid sinus cancer 10.2 HRAS PIK3CA
10 breast intraductal proliferative lesion 10.2 EGFR ERBB2
11 ethmoid sinus adenocarcinoma 10.2 HRAS PIK3CA
12 apocrine adenoma 10.2 HRAS KRAS PIK3CA
13 aggressive digital papillary adenocarcinoma 10.2 HRAS KRAS PIK3CA
14 benign struma ovarii 10.2 HRAS RET
15 paronychia 10.2 EGFR HRAS KRAS
16 bile duct cysts 10.2 HRAS KRAS
17 progesterone-receptor negative breast cancer 10.2 EGFR ERBB2
18 spinal chordoma 10.2 EGFR PDGFRA PIK3CA
19 breast scirrhous carcinoma 10.2 EGFR ERBB2
20 colorectal adenocarcinoma 10.1 EGFR HRAS KRAS
21 breast squamous cell carcinoma 10.1 EGFR ERBB2 PIK3CA
22 estrogen-receptor positive breast cancer 10.1 EGFR ERBB2 PIK3CA
23 intestinal disease 10.1 EGFR HRAS KRAS PIK3CA
24 malignant peripheral nerve sheath tumor 10.1 EGFR NRG1 PDGFRA
25 ovarian cancer 1 10.1 ERBB2 KRAS PIK3CA
26 multiple mucosal neuroma 10.1 ENO2 RET
27 oral cavity cancer 10.1 EGFR ERBB2 PIK3CA
28 malignant ectomesenchymoma 10.1 ENO2 HRAS
29 serous cystadenocarcinoma 10.1 ERBB2 HRAS PIK3CA
30 mucinous adenocarcinoma 10.1 ALK EGFR KRAS NRG1
31 cystadenocarcinoma 10.1 ERBB2 HRAS PIK3CA
32 uterine corpus serous adenocarcinoma 10.1 ERBB2 PIK3CA
33 ectomesenchymoma 10.1 ENO2 HRAS
34 ovarian serous cystadenocarcinoma 10.1 ERBB2 HRAS PIK3CA
35 endometrial adenocarcinoma 10.1 EGFR ERBB2 KRAS
36 primary peritoneal carcinoma 10.1 EGFR ERBB2 RET
37 neurofibromatosis, type iv, of riccardi 10.0 HRAS PDGFRA RET
38 colonic disease 10.0 EGFR HRAS KRAS RET
39 thyroid cancer, nonmedullary, 2 10.0 HRAS PIK3CA RET
40 pulmonary large cell neuroendocrine carcinoma 10.0 ENO2 ROS1
41 duodenum cancer 10.0 ENO2 HRAS KRAS
42 liver angiosarcoma 10.0 ENO2 HRAS KRAS
43 gastric leiomyosarcoma 10.0 ENO2 PDGFRA
44 nevus, epidermal 10.0 FGFR3 HRAS KRAS PIK3CA
45 large cell carcinoma 10.0 EGFR ENO2 ROS1
46 breast adenocarcinoma 10.0 EGFR ERBB2 KRAS PIK3CA
47 uterine carcinosarcoma 10.0 EGFR ERBB2 HRAS PIK3CA
48 gallbladder cancer 10.0 EGFR ERBB2 KRAS PIK3CA
49 adenoid cystic carcinoma 10.0 ERBB2 HRAS KRAS PIK3CA
50 ovary adenocarcinoma 10.0 ERBB2 HRAS KRAS PIK3CA

Graphical network of the top 20 diseases related to Adenosquamous Lung Carcinoma:



Diseases related to Adenosquamous Lung Carcinoma

Symptoms & Phenotypes for Adenosquamous Lung Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 61)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.28 HRAS EGFR KRAS PIK3CA
2 Decreased viability GR00106-A-0 11.28 KRAS
3 Decreased viability GR00173-A 11.28 PDGFRA
4 Decreased viability GR00221-A-1 11.28 FGFR3 HRAS PDGFRA EGFR KRAS PIK3CA
5 Decreased viability GR00221-A-2 11.28 FGFR3 HRAS KRAS PIK3CA DDR2 RET
6 Decreased viability GR00221-A-3 11.28 ERBB2 FGFR3 HRAS PDGFRA
7 Decreased viability GR00221-A-4 11.28 ERBB2 PDGFRA EGFR PIK3CA DDR2 RET
8 Decreased viability GR00231-A 11.28 RET
9 Decreased viability GR00301-A 11.28 KRAS RET
10 Decreased viability GR00342-S-1 11.28 ROS1 ARAF
11 Decreased viability GR00342-S-2 11.28 ARAF
12 Decreased viability GR00342-S-3 11.28 ARAF
13 Decreased viability GR00381-A-1 11.28 KRAS
14 Decreased viability GR00402-S-2 11.28 ERBB2 FGFR3 HRAS PDGFRA EGFR KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.25 FGFR3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.25 PIK3CA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.25 ERBB2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 10.25 RET
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.25 RET
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.25 PIK3CA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.25 RET
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.25 PIK3CA
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.25 FGFR3
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.25 ERBB2 FGFR3 PIK3CA RET
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.25 ERBB2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.21 DDR2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.21 DDR2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.21 FGFR3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.21 EGFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.21 EGFR FGFR3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.21 RET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.21 RET
33 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 DDR2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.21 ERBB2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.21 ERBB2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.21 RET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.21 ERBB2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.21 DDR2
39 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.21 RET
40 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.21 DDR2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.21 EGFR
42 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.21 ERBB2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.21 EGFR
44 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 EGFR
45 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.21 DDR2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.21 RET
47 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.21 ERBB2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 DDR2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.21 EGFR
50 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.21 FGFR3 RET

MGI Mouse Phenotypes related to Adenosquamous Lung Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 BIRC5 CD74 DDR2 EGFR ENO2 ERBB2
2 growth/size/body region MP:0005378 10.37 ALK ARAF CD74 DDR2 EGFR ENO2
3 endocrine/exocrine gland MP:0005379 10.31 ALK ARAF BIRC5 DDR2 EGFR ERBB2
4 mortality/aging MP:0010768 10.3 ALK ARAF BIRC5 CD74 DDR2 EGFR
5 homeostasis/metabolism MP:0005376 10.29 ALK BIRC5 DDR2 EGFR ERBB2 FGFR3
6 behavior/neurological MP:0005386 10.28 ALK ARAF ENO2 ERBB2 FGFR3 HRAS
7 craniofacial MP:0005382 10.17 DDR2 EGFR ENO2 ERBB2 FGFR3 HRAS
8 digestive/alimentary MP:0005381 10.16 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
9 embryo MP:0005380 10.15 BIRC5 EGFR ERBB2 KIF5B KRAS PDGFRA
10 integument MP:0010771 10.15 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
11 nervous system MP:0003631 10.11 ALK DDR2 EGFR ENO2 ERBB2 FGFR3
12 neoplasm MP:0002006 10.1 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
13 muscle MP:0005369 10.03 ARAF DDR2 EGFR ERBB2 KRAS PDGFRA
14 limbs/digits/tail MP:0005371 10.02 DDR2 EGFR ERBB2 FGFR3 KRAS PDGFRA
15 no phenotypic analysis MP:0003012 9.97 DDR2 EGFR FGFR3 HRAS KRAS PDGFRA
16 normal MP:0002873 9.86 BIRC5 EGFR ERBB2 FGFR3 HRAS KRAS
17 reproductive system MP:0005389 9.85 ALK DDR2 EGFR ERBB2 FGFR3 KRAS
18 respiratory system MP:0005388 9.61 ALK EGFR ENO2 ERBB2 FGFR3 HRAS
19 skeleton MP:0005390 9.32 ALK CD74 DDR2 EGFR ERBB2 FGFR3

Drugs & Therapeutics for Adenosquamous Lung Carcinoma

Drugs for Adenosquamous Lung Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
4
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
7
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
8
Vinorelbine Approved, Investigational Phase 3,Phase 1 71486-22-1 60780 44424639
9
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
10
Vinblastine Approved Phase 3,Phase 1 865-21-4 241903 13342
11
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
12
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
13
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
14
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
16 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
17
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
18 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
21 Antiviral Agents Phase 3,Phase 2,Phase 1
22 Immunologic Factors Phase 3,Phase 2,Phase 1
23 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
24 Vitamin B Complex Phase 3,Phase 2,Phase 1
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Folate Phase 3,Phase 2,Phase 1
27 Antimetabolites Phase 3,Phase 2,Phase 1
28 Vitamin B9 Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
30 Shark Cartilage Phase 3
31 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
32 Mitogens Phase 3,Phase 2
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
34 Etoposide phosphate Phase 3,Phase 2,Phase 1
35 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
36 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
37 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
38 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
39 Cyclooxygenase 2 Inhibitors Phase 3
40 Anti-Inflammatory Agents, Non-Steroidal Phase 3
41 Analgesics Phase 3
42 Cyclooxygenase Inhibitors Phase 3
43 Antirheumatic Agents Phase 3
44 Peripheral Nervous System Agents Phase 3
45 Analgesics, Non-Narcotic Phase 3
46 Anti-Inflammatory Agents Phase 3
47
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
48
Nicotinamide Approved, Investigational Phase 2,Phase 1 98-92-0 936
49
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
50
Lenograstim Approved, Investigational Phase 2 135968-09-1

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
3 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
4 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
5 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
6 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
7 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
8 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
9 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
12 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Unknown status NCT00227708 Phase 2 docetaxel
17 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
18 Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
19 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
20 Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC Completed NCT00030810 Phase 2 Taxotere/Cisplatin
21 Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab Completed NCT00387374 Phase 2 paclitaxel;carboplatin
22 Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00454194 Phase 2 pemetrexed disodium;sorafenib tosylate
23 Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00798603 Phase 2 carboplatin;pemetrexed disodium
24 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
25 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
26 Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00118183 Phase 2 docetaxel;bortezomib
27 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
28 Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery Completed NCT00551369 Phase 2
29 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
30 SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002642 Phase 2 cisplatin;etoposide
31 Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer Completed NCT00003202 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
32 Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00023673 Phase 1, Phase 2 carboplatin;paclitaxel
33 Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00276588 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
34 Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT01302808 Phase 1, Phase 2 erlotinib hydrochloride;romidepsin
35 Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed NCT00346320 Phase 2
36 Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00293280 Phase 2 lomustine
37 Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00550537 Phase 2 bevacizumab;carboplatin;erlotinib hydrochloride;paclitaxel
38 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00006378 Phase 2 carboplatin;paclitaxel
39 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer Completed NCT00080938 Phase 2 Temozolomide
40 Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00077311 Phase 2 cisplatin;docetaxel;BNP7787
41 Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00025285 Phase 2 carboplatin;irinotecan hydrochloride;thalidomide
42 TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00036920 Phase 2 canfosfamide hydrochloride
43 Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer Completed NCT00006004 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
44 Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Completed NCT00005850 Phase 2 cisplatin;fluoxetine;gemcitabine hydrochloride
45 Icotinib for Completed Resected IB NSCLC With EGFR Mutation Recruiting NCT02264210 Phase 2 Icotinib
46 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting NCT02186847 Phase 2 Carboplatin;Metformin Hydrochloride;Paclitaxel
47 Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
48 Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer Active, not recruiting NCT00126581 Phase 2 Carboplatin;Erlotinib Hydrochloride;Paclitaxel
49 Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT01059188 Phase 2 cetuximab;cisplatin;docetaxel
50 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Active, not recruiting NCT00979212 Phase 2 panitumumab;carboplatin;paclitaxel

Search NIH Clinical Center for Adenosquamous Lung Carcinoma

Genetic Tests for Adenosquamous Lung Carcinoma

Anatomical Context for Adenosquamous Lung Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Adenosquamous Lung Carcinoma:

19
Lung

MalaCards organs/tissues related to Adenosquamous Lung Carcinoma:

41
Lung, Bone, Breast, Ovary, Prostate, Pancreas, Thyroid

Publications for Adenosquamous Lung Carcinoma

Articles related to Adenosquamous Lung Carcinoma:

(show all 16)
# Title Authors Year
1
Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. ( 29258673 )
2018
2
[Progression of diagnosis and treatment for adenosquamous lung carcinoma]. ( 28550661 )
2017
3
Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods. ( 26923333 )
2016
4
Surgical specimen histology revealed inadequacy of conventional transbronchial needle aspiration sample in the diagnosis of adenosquamous lung carcinoma. ( 25973234 )
2015
5
Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma. ( 26072072 )
2015
6
EGFR gene mutations in patients with adenosquamous lung carcinoma. ( 24575772 )
2014
7
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma. ( 24838432 )
2014
8
Synchronous left atrial myxoma and adenosquamous lung carcinoma. ( 23924482 )
2013
9
The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib. ( 23037472 )
2012
10
Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. ( 15784375 )
2005
11
Adenosquamous lung carcinoma: clinical characteristics, surgical treament and prognosis. ( 12906147 )
2000
12
The adenosquamous lung carcinoma: clinical and pathological characteristics. ( 7698972 )
1994
13
DNA ploidy pattern of each carcinomatous component in adenosquamous lung carcinoma. ( 8452418 )
1993
14
The increasing recognition of adenosquamous lung carcinoma (1977-1986). ( 1514535 )
1992
15
Clinical features of adenosquamous lung carcinoma in 127 patients. ( 2368969 )
1990
16
Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. ( 3675050 )
1987

Variations for Adenosquamous Lung Carcinoma

Cosmic variations for Adenosquamous Lung Carcinoma:

9 (show top 50) (show all 13824)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 10
2 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 10
3 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 10
4 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 10
5 COSM6145051 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.562G>T p.A188S 16:72959584-72959584 10
6 COSM6978013 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1855C>G p.H619D 16:72958291-72958291 10
7 COSM6956103 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2437A>T p.T813S 16:72957709-72957709 10
8 COSM6826441 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 10
9 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 10
10 COSM6932802 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2842G>T p.A948S 16:72950843-72950843 10
11 COSM6954614 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 10
12 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 10
13 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 10
14 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 10
15 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 10
16 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 10
17 COSM6965155 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 10
18 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 10
19 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 10
20 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 10
21 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 10
22 COSM6964729 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5670G>C p.Q1890H 16:72797012-72797012 10
23 COSM6931279 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1530G>T p.E510D 16:72958616-72958616 10
24 COSM6935718 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 10
25 COSM6929247 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8677G>C p.G2893R 16:72794005-72794005 10
26 COSM6945078 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 10
27 COSM6935881 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1352G>T p.C451F 16:72958794-72958794 10
28 COSM6940635 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 10
29 COSM6969446 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 10
30 COSM6968693 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 10
31 COSM6926443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10885C>G p.P3629A 16:72787391-72787391 10
32 COSM6962405 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 10
33 COSM6970007 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 10
34 COSM6977567 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 10
35 COSM5796563 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.445C>T p.Q149* 16:72959701-72959701 10
36 COSM6966467 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5788T>C p.S1930P 16:72796894-72796894 10
37 COSM6970295 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 10
38 COSM6968715 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 10
39 COSM6982440 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 10
40 COSM6983995 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7133C>G p.T2378S 16:72795549-72795549 10
41 COSM6962938 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4181C>A p.S1394* 16:72798501-72798501 10
42 COSM6937443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 10
43 COSM6953061 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10994A>T p.D3665V 16:72787282-72787282 10
44 COSM6953714 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3431G>T p.C1144F 16:72889748-72889748 10
45 COSM6969956 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.527G>T p.G176V 16:72959619-72959619 10
46 COSM4062722 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2486T>C p.M829T 16:72957660-72957660 10
47 COSM6939807 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1408G>T p.E470* 16:72958738-72958738 10
48 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 2:97737758-97737758 10
49 COSM95551 YWHAE lung,NS,carcinoma,adenocarcinoma c.146A>G p.Y49C 17:1364977-1364977 10
50 COSM48846 YES1 lung,NS,carcinoma,adenocarcinoma c.473G>T p.W158L 18:746049-746049 10

Expression for Adenosquamous Lung Carcinoma

Search GEO for disease gene expression data for Adenosquamous Lung Carcinoma.

Pathways for Adenosquamous Lung Carcinoma

Pathways related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.24 ARAF BIRC5 EGFR ERBB2 FGFR3 HRAS
2
Show member pathways
14.11 ARAF BIRC5 CD74 EGFR ERBB2 FGFR3
3
Show member pathways
13.93 ALK ARAF DDR2 EGFR ERBB2 FGFR3
4
Show member pathways
13.79 ALK ARAF BIRC5 DDR2 EGFR ERBB2
5
Show member pathways
13.78 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
6
Show member pathways
13.76 ALK ARAF DDR2 EGFR ERBB2 FGFR3
7
Show member pathways
13.66 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
8
Show member pathways
13.6 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
9
Show member pathways
13.56 CD74 EGFR ERBB2 FGFR3 HRAS KIF5B
10
Show member pathways
13.56 ALK ARAF DDR2 EGFR ERBB2 FGFR3
11
Show member pathways
13.51 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
12
Show member pathways
13.4 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
13
Show member pathways
13.39 ARAF BIRC5 EGFR ERBB2 FGFR3 HRAS
14
Show member pathways
13.37 EGFR ERBB2 FGFR3 HRAS KRAS NRG1
15
Show member pathways
13.28 ALK ARAF DDR2 EGFR ERBB2 FGFR3
16
Show member pathways
13.25 ARAF EGFR ERBB2 HRAS KRAS NRG1
17
Show member pathways
13.18 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
18
Show member pathways
13.17 ALK DDR2 EGFR FGFR3 HRAS KRAS
19
Show member pathways
13.16 ARAF EGFR FGFR3 HRAS KRAS NRG1
20
Show member pathways
13.13 BIRC5 EGFR HRAS KRAS PDGFRA PIK3CA
21
Show member pathways
13.12 ALK DDR2 EGFR ERBB2 FGFR3 HRAS
22
Show member pathways
13.1 EGFR ERBB2 FGFR3 HRAS KRAS PDGFRA
23
Show member pathways
13.02 ARAF EGFR ERBB2 HRAS KRAS PDGFRA
24
Show member pathways
13 ARAF EGFR HRAS KRAS PDGFRA PIK3CA
25
Show member pathways
13 ARAF EGFR ERBB2 HRAS KRAS PIK3CA
26
Show member pathways
12.97 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
27
Show member pathways
12.92 ARAF BIRC5 EGFR ERBB2 HRAS KRAS
28 12.9 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
29
Show member pathways
12.87 ARAF EGFR ERBB2 HRAS KRAS PIK3CA
30
Show member pathways
12.85 ARAF BIRC5 HRAS KRAS PIK3CA
31
Show member pathways
12.84 EGFR FGFR3 HRAS KRAS PDGFRA PIK3CA
32
Show member pathways
12.81 EGFR ERBB2 FGFR3 HRAS KRAS NRG1
33
Show member pathways
12.8 ERBB2 HRAS KRAS NRG1 PIK3CA
34
Show member pathways
12.77 ARAF EGFR HRAS KRAS PDGFRA
35 12.76 ARAF EGFR FGFR3 HRAS KRAS PDGFRA
36 12.72 ALK ARAF BIRC5 EGFR ERBB2 FGFR3
37
Show member pathways
12.71 BIRC5 EGFR ERBB2 HRAS KRAS PDGFRA
38
Show member pathways
12.69 ALK ARAF EGFR ERBB2 FGFR3 HRAS
39
Show member pathways
12.66 ARAF EGFR ERBB2 HRAS KRAS NRG1
40
Show member pathways
12.62 FGFR3 HRAS KRAS PIK3CA
41 12.62 EGFR ERBB2 FGFR3 HRAS KRAS PDGFRA
42
Show member pathways
12.58 ARAF EGFR ERBB2 HRAS KRAS NRG1
43
Show member pathways
12.56 ARAF HRAS KRAS PIK3CA
44
Show member pathways
12.54 ERBB2 HRAS KRAS PIK3CA
45
Show member pathways
12.54 EGFR ERBB2 FGFR3 HRAS KRAS PDGFRA
46
Show member pathways
12.52 EGFR HRAS KRAS PDGFRA PIK3CA
47 12.52 EGFR FGFR3 HRAS KIF5B PDGFRA
48
Show member pathways
12.52 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
49
Show member pathways
12.51 EGFR HRAS KRAS PDGFRA PIK3CA
50
Show member pathways
12.49 FGFR3 HRAS KRAS PIK3CA

GO Terms for Adenosquamous Lung Carcinoma

Cellular components related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.81 ALK DDR2 EGFR ERBB2 FGFR3 NRG1
2 perinuclear region of cytoplasm GO:0048471 9.8 EGFR ERBB2 HRAS KIF5B ROS1
3 plasma membrane GO:0005886 9.8 ALK CD74 DDR2 EGFR ENO2 ERBB2
4 cell surface GO:0009986 9.77 CD74 EGFR FGFR3 PDGFRA ROS1
5 receptor complex GO:0043235 9.23 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
6 membrane GO:0016020 10.2 ALK CD74 DDR2 EGFR ENO2 ERBB2
7 cytoplasm GO:0005737 10.13 ALK BIRC5 DDR2 EGFR ENO2 ERBB2

Biological processes related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol phosphorylation GO:0046854 9.99 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
2 positive regulation of MAPK cascade GO:0043410 9.98 CD74 EGFR ERBB2 FGFR3 HRAS PDGFRA
3 positive regulation of cell migration GO:0030335 9.95 EGFR HRAS PDGFRA RET
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.95 ALK DDR2 EGFR ERBB2 PDGFRA RET
5 negative regulation of neuron apoptotic process GO:0043524 9.92 BIRC5 HRAS KRAS PIK3CA
6 activation of MAPK activity GO:0000187 9.91 ALK CD74 NRG1 RET
7 MAPK cascade GO:0000165 9.91 ARAF EGFR ERBB2 FGFR3 HRAS KRAS
8 wound healing GO:0042060 9.89 EGFR ERBB2 NRG1 PDGFRA
9 positive regulation of MAP kinase activity GO:0043406 9.88 EGFR ERBB2 HRAS KRAS
10 positive regulation of fibroblast proliferation GO:0048146 9.86 CD74 DDR2 EGFR PDGFRA
11 ERBB2 signaling pathway GO:0038128 9.85 EGFR ERBB2 NRG1 PIK3CA
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 ARAF EGFR PIK3CA
13 liver development GO:0001889 9.83 EGFR KRAS PIK3CA
14 positive regulation of epithelial cell proliferation GO:0050679 9.81 EGFR ERBB2 HRAS
15 regulation of cell motility GO:2000145 9.79 EGFR ERBB2 NRG1
16 regulation of ERK1 and ERK2 cascade GO:0070372 9.78 EGFR ERBB2 ROS1
17 negative regulation of signal transduction GO:0009968 9.76 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
18 regulation of TOR signaling GO:0032006 9.67 ARAF ROS1
19 positive regulation of phospholipase C activity GO:0010863 9.67 HRAS PDGFRA
20 chondrocyte proliferation GO:0035988 9.66 DDR2 FGFR3
21 endochondral bone growth GO:0003416 9.65 DDR2 FGFR3
22 response to isolation stress GO:0035900 9.64 HRAS KRAS
23 negative regulation of ERBB signaling pathway GO:1901185 9.63 EGFR ERBB2
24 peptidyl-tyrosine phosphorylation GO:0018108 9.61 ALK DDR2 EGFR ERBB2 FGFR3 NRG1
25 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.32 ALK CD74 DDR2 EGFR ERBB2 FGFR3
26 signal transduction GO:0007165 10.25 ALK ARAF CD74 DDR2 EGFR ERBB2
27 cell differentiation GO:0030154 10.17 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
28 phosphorylation GO:0016310 10.16 ALK ARAF DDR2 EGFR ERBB2 FGFR3
29 positive regulation of cell proliferation GO:0008284 10.14 BIRC5 DDR2 EGFR FGFR3 HRAS KRAS
30 protein phosphorylation GO:0006468 10.11 ALK ARAF BIRC5 DDR2 EGFR ERBB2
31 cell proliferation GO:0008283 10.06 ALK CD74 EGFR ERBB2 HRAS ROS1
32 negative regulation of apoptotic process GO:0043066 10.06 ALK ARAF BIRC5 CD74 DDR2 EGFR
33 positive regulation of protein phosphorylation GO:0001934 10.04 ALK CD74 EGFR ERBB2 HRAS KRAS
34 positive regulation of gene expression GO:0010628 10.03 ERBB2 HRAS KRAS NRG1 RET
35 positive regulation of protein kinase B signaling GO:0051897 10.02 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
36 protein autophosphorylation GO:0046777 10 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA

Molecular functions related to Adenosquamous Lung Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.96 ALK ARAF DDR2 EGFR ERBB2 FGFR3
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.91 EGFR ERBB2 FGFR3 NRG1 PDGFRA RET
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.8 EGFR ERBB2 FGFR3 NRG1 PDGFRA PIK3CA
4 transmembrane signaling receptor activity GO:0004888 9.76 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
5 protein phosphatase binding GO:0019903 9.71 EGFR ERBB2 ROS1
6 protein tyrosine kinase activity GO:0004713 9.61 ALK DDR2 EGFR ERBB2 FGFR3 NRG1
7 ErbB-3 class receptor binding GO:0043125 9.52 ERBB2 NRG1
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.23 ALK DDR2 EGFR ERBB2 FGFR3 PDGFRA
9 protein binding GO:0005515 10.4 ALK ARAF BIRC5 CD74 DDR2 EGFR
10 ATP binding GO:0005524 10.2 ALK ARAF DDR2 EGFR ERBB2 FGFR3
11 transferase activity GO:0016740 10.18 ALK ARAF DDR2 EGFR ERBB2 FGFR3
12 identical protein binding GO:0042802 10.05 ALK BIRC5 CD74 EGFR ERBB2 FGFR3
13 protein kinase activity GO:0004672 10.02 ALK ARAF DDR2 EGFR ERBB2 FGFR3
14 nucleotide binding GO:0000166 10.01 ARAF EGFR ERBB2 FGFR3 HRAS KRAS

Sources for Adenosquamous Lung Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....